ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Protocolized, Broad-Based Renal Genetic Testing in the Management of Patients at a Transplant Center

V. Paramasivam1, P. Shehzad1, B. Greco1, K. Gaj2, M. Germain3

1Baystate Medical Center, Springfield, MA, 2Natera, Inc., Austin, TX, 3Renal Transplant Associates of New England, Springfield, MA

Meeting: 2022 American Transplant Congress

Abstract number: 506

Keywords: Gene polymorphism, Kidney

Topic: Clinical Science » Kidney » 49 - Recurrent Kidney Disease & Genetics

Session Information

Session Name: Recurrent Kidney Disease & Genetics

Session Type: Rapid Fire Oral Abstract

Date: Tuesday, June 7, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 6:40pm-6:50pm

Location: Hynes Room 310

*Purpose: Studies show that ~10% of adult chronic kidney diseases (CKD) cases have genetic etiologies. In the nephrology setting, the use of a broad, unbiased genetic panel may have benefit over using smaller, targeted panels based on the clinical presentation. Here we describe the use of an NGS-based panel of 382 or 385 genes related to kidney disease (the RenasightTM test), in our transplant nephrology center.

*Methods: From November 2020-2021 our center incorporated genetic testing for select donors, patients with CKD, and kidney transplant (KT) recipients. Patients were offered genetic testing if they met one of the following criteria: (i) KT recipient, (ii) history of undiagnosed kidney disease, (iii) family history of kidney disease or (iv) African American ancestry. Prospective donors were offered testing if there was a family history of kidney disease and/or if they were of African American descent. The presence of 1 pathogenic (P)/likely pathogenic (LP) variant in an X-linked or autosomal dominant condition, 2 P/LP variants in an autosomal recessive condition, or 2 APOL1 G1 or G2 alleles were considered positive findings.

*Results: A total of 114 patients fit the testing criteria (KT recipients: n=33, CKD/waitlisted: n=75; donors: n=6), of which, 56% were male (n=62) with an average age of 49 years (range: 7-81). The clinical diagnoses of the tested CKD and KT patients were classified in 7 categories (Table 1); of which, the most common were glomerular disease (n=37, 32.46%), nephropathy of unknown cause (n=24, 21.05%) and hypertensive nephropathy (n=17, 14.91%). Overall, 31.6% (36/114) patients had positive findings in 13 genes; 2 patients had dual positive results (Table 1). None (0/6) of the prospective donors had positive findings. Notably, genetic findings lead to disease reclassification or immediate change in management in 29 of the 108 CKD/KT patients.

*Conclusions: Incorporating broad panel genetic testing into clinical practice at a transplant nephrology center yielded valuable genetic insights for patients with CKD, KT and potential donors. In multiple affected patients, the clinical presentation did not align with the genetic diagnosis, leading to reclassification of disease. Unanticipated negative results for some patients prompted additional workup. This experience demonstrates that implementing protocolized genetic testing with a broad gene panel can identify patients with CKD for which testing is appropriate.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Paramasivam V, Shehzad P, Greco B, Gaj K, Germain M. Protocolized, Broad-Based Renal Genetic Testing in the Management of Patients at a Transplant Center [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/protocolized-broad-based-renal-genetic-testing-in-the-management-of-patients-at-a-transplant-center/. Accessed June 16, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences